Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 14, 2018
Pharmacy Choice - Pharmaceutical News - FDA releases gene therapy guidance documents - November 14, 2018

Pharmacy News Article

 7/11/18 - FDA releases gene therapy guidance documents

FDA Wednesday released six draft guidance documents on gene therapy: three advising companies on how to use the technology to treat certain diseases, two about manufacturing and one on the design of long term follow up studies.

The disease-specific draft guidance documents provide advice about developing gene therapies for hemophilia, retinal disorders and rare diseases.

Rare diseases are attractive targets for gene therapy because 80% are the result of single-gene defects, and the lack of effective therapies represents a large unmet need, FDA Commissioner Scott Gottlieb said in a statement.

The hemophilia guidance includes recommendations on the use of factor activity levels as a surrogate endpoint for accelerated approval.

One of the draft manufacturing guidance documents covers testing of retroviral vector-based gene therapies for replication competent retrovirus during manufacturing and patient follow up. The other provides recommendations regarding CMC information in IND submissions for human gene therapies.

The new guidance documents follow three FDA approvals of gene therapies over the last year: the retinal dystrophy therapy Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) and the CAR T cancer therapies Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from Gilead Sciences Inc.

Gottlieb noted differences between regulating gene therapies and other kinds of biopharmaceuticals. "In contrast to traditional drug review, some of the more challenging questions when it comes to gene therapy relate to product manufacturing and quality, or questions about the durability of response, which often can't be fully answered in any reasonably sized pre-market trial," he wrote.

These challenges mean that for some gene therapy products, "we may need to accept some level of uncertainty around these questions at the time of approval," he wrote.

Addressing uncertainty about long-term durability and safety through post-market follow-up studies will be critical to advancing gene therapy, Gottlieb said.

.



(C) 2018 M2 COMMUNICATIONS

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 15: The New Hypertension Guidelines: What are They Telling Us?
Last Chance
Nov 16: Influenza Update 2018-2019 Season
Nov 18: Establishing a Patient Communication Plan in Your Pharmacy
Nov 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Nov 20: Acne Vulgaris: Comprehensive Pharmaceutical Care
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415